Larimar Therapeutics, Inc.
nomlabofusp
Friedreich’s ataxia
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for nomlabofusp in Friedreich’s ataxia are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patient expected mid-2026.”